Abstract
Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.
| Original language | English |
|---|---|
| Pages (from-to) | e45-e56 |
| Journal | The Lancet Oncology |
| Volume | 22 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2021 |
Bibliographical note
Funding Information:RAA received non-financial support from Roche Diagnostics, outside the submitted work. JB received financial support from the Boyne Research Institute. CS received grants from the Sony Foundation and Merck Serono, during the conduct of the project. HMvS received funding from Pfizer and Ferring, outside the submitted work. All other authors declare no competing interests.
Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). We thank Teresa Woodruff (Northwestern University, Chicago, IL, USA), Anja Borgmann-Staudt (Charité Universitätsmedizin, Berlin, Germany), Yasmin Jayasinghe (The Royal Children's Hospital, Melbourne, VIC, Australia), and Joyce Reinecke (Alliance for Fertility Preservation, Lafayette, CA, USA) for critically appraising the recommendations and manuscript as external reviewers and Alexandra Brownsdon (University College London Hospitals NHS Foundation Trust, London, UK) as a patient advocate. We also thank the PanCareLIFE Consortium ( appendix p 2 ). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). We thank Teresa Woodruff (Northwestern University, Chicago, IL, USA), Anja Borgmann-Staudt (Charit? Universit?tsmedizin, Berlin, Germany), Yasmin Jayasinghe (The Royal Children's Hospital, Melbourne, VIC, Australia), and Joyce Reinecke (Alliance for Fertility Preservation, Lafayette, CA, USA) for critically appraising the recommendations and manuscript as external reviewers and Alexandra Brownsdon (University College London Hospitals NHS Foundation Trust, London, UK) as a patient advocate. We also thank the PanCareLIFE Consortium (appendix p 2). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Publisher Copyright:
© 2021 Elsevier Ltd
Research programs
- EMC MM-02-54-03
